Editas' Zero Crisis Sickle Cell Therapy Ignites Biotech's Quiet ComebackGlobal Report·Oct 20, 2026 at 10:15 AMEDIT-3.61%DRMA-9.61%
PharmaCyte Biotech 2026: Revenue $0 Net income ($5.79M), EPS ($0.54) — 10-Q SummaryTradingView·Sep 14, 2026 at 08:11 PMPMCB+1.49%
PharmaCyte net loss widens to $19.42 million in FY26; revenue remains no revenuePUBT·Jul 29, 2026 at 09:20 PMPMCB+1.49%
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga_article·Jun 2, 2026 at 09:09 PMCPHI-2.67%NRXP+3.75%
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga_article·May 18, 2026 at 09:05 PMBLRX-1.16%NCNA+2.64%
07:30 ETPackGene to Present Advances in Scalable AAV Manufacturing, Analytical Innovation, and Novel Capsid Engineering at ASGCT 2026prnewswire·May 5, 2026 at 11:38 AMNKGN+300.00%PRTG0.00%
Mankind Pharma shares gain 3% on acquiring Rivotril brand rights from RocheBusiness Standard·Mar 17, 2026 at 09:51 PMIHI+0.09%LONA-2.62%
PharmaCyte Biotech 10-Q: $0.0M Revenue, $(0.17) EPS (Q3), $(2.41) EPS (YTD)TradingView·Mar 17, 2026 at 07:51 PMPMCB+1.49%
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2026 | PBSV Stock NewsStockTitan·Mar 17, 2026 at 01:05 PMLABD+4.46%IHE-2.17%
Cipher Pharmaceuticals Delivers Record 2025 Results and Primes for Next Acquisition PhaseTip Ranks·Mar 12, 2026 at 10:09 PMPBE-0.67%LABU-4.18%
